Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13752
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLo, J-
dc.contributor.authorPapa, Nathan P-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorMurphy, Declan-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2015-12-15-
dc.date.accessioned2016-03-31T05:40:00Z-
dc.date.accessioned2016-03-31T05:40:12Z-
dc.date.available2016-03-31T05:40:12Z-
dc.date.available2016-03-31T05:40:00Z-
dc.date.issued2016-
dc.identifier.citationProstate international 2016, vol. 4(1) p. 20-4en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13752-
dc.description.abstractBACKGROUND: Approaches to prostate cancer (PCa) care have changed in recent years out of concern for overdiagnosis and overtreatment. Despite these changes, many patients continue to undergo some form of curative treatment and with a growing perception among multidisciplinary clinicians that more aggressive treatments are being favored. This study examines patterns of PCa care in Australia, focusing on current rates of screening and aggressive interventions that consist of high-dose-rate (HDR) brachytherapy and pelvic lymph node dissection (PLND). METHODS: Health services data were used to assess Australian men undergoing PCa screening and treatment from 2001 to 2014. Age-specific rates of prostate-specific antigen (PSA) screening were calculated. Ratios of radical prostatectomy (RP) with PLND to RP without PLND, and HDR brachytherapy to low-dose-rate (LDR) brachytherapy were determined by state jurisdictions. RESULTS: From 2008, the rate of PSA screening trended downward significantly with year for all age ranges (P < 0.02) except men aged ≥ 85 (P = 0.56). PLND rates for 2008-2014 were lower than rates for 2001-2007 across all states and territories. From 2008 to 2014, PLND was performed ≥ 2.7 times more frequently in New South Wales and the Australian Capital Territory than in other jurisdictions. Since 2007, brachytherapy practice across Australia has evolved towards a relatively low use of HDR brachytherapy (ratio of HDR to LDR brachytherapy < 0.5 for all jurisdictions except the Australian Capital Territory). CONCLUSION: Rates of PLND and HDR brachytherapy for PCa have declined in Australia, providing evidence for the effect of stage migration due to widespread PSA screening. Currently, PSA screening rates remain high among older men, which may expose them to unnecessary investigations and treatment-related morbidity.en_US
dc.subjectBrachytherapyen_US
dc.subjectProstatectomyen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectMass Screeningen_US
dc.subjectLymph Node Excisionen_US
dc.titleAustralian patterns of prostate cancer care: Are they evolving?en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAustralian patterns of prostate cancer care: Are they evolving?en_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centreen_US
dc.identifier.affiliationUniversity of Melbourne, Department of Surgery, Austin Healthen_US
dc.type.studyortrialReviews/Systematic Reviewsen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27014660en_US
dc.identifier.doi10.1016/j.prnil.2015.11.001en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.